Wharton’s Jelly mesenchymal stromal cells were safe but did not improve COVID-19 ARDS outcomes in a randomized pilot trial

Torres and colleagues report the COVIDMES multicenter Phase I/II pilot trial of Wharton’s Jelly-derived mesenchymal stromal cells in hospitalized patients with moderate-to-severe COVID-19 ARDS. Twenty-six patients were enrolled and 25 received two intravenous doses: 13 received 1×10^6 viable cells per kilogram and 12 received placebo. No treatment-related serious adverse events occurred. There was no statistically significant difference in 28-day mortality: zero deaths with MSC treatment versus two with placebo, P=0.18. Mechanical ventilation lasted 18.3 days with MSCs and 10.6 days with placebo, P=0.08. ICU stay was 17.1 versus 11.9 days, P=0.11. Ferritin declined more over time in the MSC group, but the biomarker change was not linked to clinical improvement. This is a useful negative study for the MSC evidence base. It supports short-term feasibility and safety in this small setting, but it does not support efficacy for ARDS. It also shows why biomarker movement cannot substitute for survival, ventilation, or functional outcomes. The cells, dose, timing, and disease context are specific. The result should not be generalized to frailty, osteoarthritis, Alzheimer’s disease, or commercial anti-aging infusions.

In this exploratory pilot study, WJ-MSCs demonstrated a favorable safety profile and evidence of biochemical immunomodulation but no clinical efficacy in moderate-to-severe COVID-19 associated ARDS. These findings highlight the challenges of evaluating advanced therapy medicinal produkter within a rapidly evolving standard of care and support the need for biomarker-guided patient stratification and optimized dosing strategies in future MSC trials. The successful execution of this trial also validates the resilience of academic "donor-to-patient" networks in global health emergencies.